Low natural killer activity and central nervous system disease as a high‐risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis
Open Access
- 23 May 2002
- Vol. 94 (11) , 3023-3031
- https://doi.org/10.1002/cncr.10515
Abstract
BACKGROUND Familial hemophagocytic lymphohistiocytosis HLH (FHL) is fatal, unless patients are rescued with hematopoietic stem cell transplantation (SCT). Although the molecular identification of FHL now is possible at least in part from perforin gene study, many cases escape detection or never are tested due to the lack of specific hallmarks, making diagnosis difficult. To the authors' knowledge, it remains to be determined whether persistently low natural killer cell (NK) activity and a high incidence of central nervous system (CNS) disease increase the probability of FHL. METHODS The authors analyzed 42 HLH patients age < 2 years, 13 of whom developed overt CNS disease and 5 of whom demonstrated persistently deficient NK activity (Group 1). The remaining 24 patients had no CNS disease and had NK activity of moderate decrease to within the normal range (Group 2). RESULTS In Group 1, CNS symptoms were detected in 6 cases within 1 month and between 4.5–9 months in 6 other patients. In these cases, spotty lesions demonstrating a high T2 signal in the white matter were noted on brain magnetic resonance imaging. The survival was significantly poor for patients in Group 1 unless they were rescued with SCT, which was performed in 5 of the 13 patients with CNS disease and in all 5 patients with persistent NK activity deficiency. SCT was successful in 9 patients, with no CNS sequelae reported after the transplantation. Conversely, the prognosis of the 24 patients in Group 2 was better and only 1 patient required SCT. CONCLUSIONS Very young HLH patients (age < 2 years) who are at high risk of fatal FHL with persistently deficient NK activity and/or overt CNS disease require appropriate SCT to reverse CNS disease and achieve a complete cure. Cancer 2002;94:3023–31. © 2002 American Cancer Society. DOI 10.1002/cncr.10515Keywords
This publication has 26 references indexed in Scilit:
- Treatment Strategies for Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (EBV-HLH)Leukemia & Lymphoma, 2000
- Perforin Gene Defects in Familial Hemophagocytic LymphohistiocytosisScience, 1999
- Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in JapanBone Marrow Transplantation, 1999
- Linkage of Familial Hemophagocytic Lymphohistiocytosis to 10q21-22 and Evidence for HeterogeneityAmerican Journal of Human Genetics, 1999
- Successful engraftment of unrelated cord blood stem cells for familial erythrophagocytic lymphohistiocytosisBone Marrow Transplantation, 1998
- Heterogeneity of Immune Markers in Hemophagocytic LymphohistiocytosisJournal of Pediatric Hematology/Oncology, 1998
- Hemophagocytic lymphohistiocytosis in infancy and childhoodThe Journal of Pediatrics, 1997
- Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosisThe Journal of Pediatrics, 1997
- Bone marrow transplantation during fulminant EBV-infection In Duncan's syndrome.The Lancet, 1993
- Correction of Duncan's syndrome by allogeneic bone marrow transplantationThe Lancet, 1993